SEC EDGAROCT 21 min read$CLOV

Toy Andrew sold $1.3M of CLOV

Toy Andrew (Chief Executive Officer) sold 318,806 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.19 ($1.34M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Toy Andrew

Published Oct 2, 2026, 8:12 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 2, 2026, 8:19 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CLOV

Bearish

medium confidence

Mentioned

$CLOV

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CLOVBearishLow

Why it matters

The CEO's sale may signal short‑term weakness, but the long‑term impact depends on broader company fundamentals.

Market read

Insider sell of over $1M by the CEO is a material event for CLOV, potentially prompting short‑term price adjustments.

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: after filing today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering timely insight into insider sentiment.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CLOVBearishMedium confidence

Context

CEO Toy Andrew sold 318,806 shares for $1.33M via a 10b5‑1 plan, reducing his stake to 9.14M shares.

Expected impact

likely downward pressure as investors price in the insider sell

Evidence & confidence

A $1.3M sale by the chief executive is material for a mid‑cap biotech, often interpreted as a lack of confidence or liquidity need, which can trigger short‑term selling.

Market effects

Sector

May raise concerns for other biotech firms with insider sales, but limited sector-wide impact.

Regional

Primarily U.S. market; no broader regional effect.

Global

Low global relevance; confined to CLOV shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company outlook; price may remain stable.

Key entities

Person
Toy Andrew
Chief Executive Officer of Clover Health Investments, Inc.

Read at source ← All news

SEP 15

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min

SEP 11

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

yahoo.com2 min

SEP 10

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

financialcontent.com2 min

SEP 10

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min

SEP 3

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.

insidermonkey.com3 min

AUG 20